Close
Help




JOURNAL

Clinical Medicine Insights: Gastroenterology

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease

Submit a Paper


Clinical Medicine Insights: Gastroenterology 2012:5 11-21

Review

Published on 10 Apr 2012

DOI: 10.4137/CGast.S7613


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Gastroenterology

Abstract

Treatment with Anti-Tumor Necrosis Factor (anti-TNF) therapy has become a mainstay of therapy for patients with CD who are unresponsive to conventional medical management. Currently there are three anti-TNF antibodies that have been approved by the US Food and Drug Administration for the treatment of CD, namely infliximab, adalimumab and certolizumab pegol (CZP). Several double blind placebo controlled trials determined that CZP is effective as induction and maintenance treatment in adult patients with CD regardless of their prior exposure to other anti-TNF antibodies. This review discusses the efficacy of CZP and adherence to therapy with anti-TNF antibodies in patients with CD.



Downloads

PDF  (563.81 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

Supplementary Files 1   (8.79 MB WMV FORMAT)

BibTex citation   (BIBDESK, LATEX)

XML


Video Abstract



Quick Links


New article and journal news notification services